Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Esketamine Fixed-Dose Study in Japanese Patients With Treatment-Resistant Depression
jRCT2080223353Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of esketamine in major depressive disorder (MDD) (4 arms), sponsored by Janssen Pharmaceutical. Started Oct 2016; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT2080223353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223353.